BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)
NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory diseases, announces that it will conduct a Phase 2 study of rhu-pGSN for decompression sickness (DCS) under a contract awarded by the U.S. Navy's Office of Naval Research to the University of Maryland School of Medicine (UMSOM). This work is the culmination of an extended collaboration with Dr. Stephen Thom, Professor of Emergency Medicine at UMSOM. The Company's portfolio is built around gelsolin, a highly conserved and critical immune regulatory protein which rebalances dysfunctional inflammation without suppressing immune function.
Phase 2 Clinical Trial of Rhu-pGSNThe study, 'Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers,' NCT06216366 is being conducted under a contract with the Office of Naval Research with the University of Maryland. It will investigate the use of rhu-pGSN as a pre- or post-exposure intervention in healthy trained SCUBA divers exposed to controlled hyperbaric conditions. The study is designed to assess the impact of rhu-pGSN on key inflammatory responses and microparticle production associated with decompression.
Decompression sickness occurs when inert gas bubbles form in the bloodstream and tissues due to rapid pressure changes, triggering an inflammatory cascade. Previous studies have shown that individuals with DCS exhibit depleted levels of plasma gelsolin and elevated levels of microparticles that contain inflammatory cytokines. In animal models, supplementation with rhu-pGSN both prevented and mitigated DCS-related complications.
This randomized, double-blind, placebo-controlled study will enroll healthy trained SCUBA divers at a single site and expose them to a standardized hyperbaric protocol (30 meters of seawater for 35 minutes). Participants will be randomized into three groups to receive either pre-exposure or post-exposure rhu-pGSN, or placebo. The study will assess a broad range of outcomes including plasma gelsolin levels, inflammatory markers like IL-1β, gas bubble formation, and well-being metrics.
Dr. Thom states, 'If successful, this study could transform the way we manage decompression sickness by providing a portable, field-deployable treatment option. Reducing our reliance on hyperbaric chambers would greatly expand our ability to treat DCS in remote or operational environments, improving outcomes and readiness, a key goal for the Navy.' BioAegis and University of Maryland are co-applicants on a patent filing listing Dr. Thom as an inventor.
Gelsolin: A Multitasking Protein for Complex Inflammatory ConditionsRhu-pGSN holds immense promise as a therapeutic intervention for serious acute and chronic conditions due to its multifaceted mechanism of action. In critical illness, gelsolin levels collapse, causing adverse outcomes. Supplementing gelsolin addresses this deficit directly, restoring immune balance while preserving host defense and rhu-pGSN has been shown in animal studies to:
Modulate the activation of the NLRP3 inflammasome.
Enhance uptake and killing of microbial pathogens by innate immune cells.
Bind to and remove harmful inflammatory mediators and toxic actin released from damaged cells.
Regulate macrophage phenotype to modulate inflammation.
Supplementation with the recombinant gelsolin protein holds promise to address the overzealous inflammatory response associated many inflammatory diseases without suppressing immune function.
About BioAegisBioAegis Therapeutics Inc. is a NJ-based clinical-stage private company whose mission is to capitalize on a key regulatory component of the body's immune system, plasma gelsolin, to prevent adverse outcomes in diseases driven by inflammation.
BioAegis has the exclusive license to broad, worldwide intellectual property through Harvard-Brigham and Women's Hospital. It holds over 40 patents issued for coverage of inflammatory disease, infection, renal failure, neurologic disease, and frailty. BioAegis will also have U.S. biologics exclusivity and has recently filed new IP in areas of unmet need.
BioAegis' lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS). This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00067. NCT05947955
Investor Inquiries:Steven Cordovano203-952-6373scordovano@bioaegistx.com
Media Inquiries:Christine Laganaclagana@bioaegistx.com
This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a day ago
- Business Upturn
The Texas Chiropractic Association (TCA) Recognizes Parker University and Several Alumni at Chiro Texpo 2025
By GlobeNewswire Published on July 12, 2025, 02:43 IST Dallas, Texas, July 11, 2025 (GLOBE NEWSWIRE) — The Texas Chiropractic Association (TCA) recently recognized chiropractic leaders during Chiro Texpo 2025, the annual state chiropractic convention, which was held at the Hyatt Regency Frisco-Dallas in Frisco. TCA is the voice for chiropractic in Texas, providing protection, state-wide advocacy, information, and education for more than 7,000 DCs who are licensed to practice in Texas. TCA advocates the position that citizens of Texas should have adequate access to the healthcare of their choice and that DCs are adequately represented in the government's decision-making process. Awards were presented to Texas chiropractors and other chiropractic supporters at the President's Gala, with Parker University alumni walking away with awards from key categories. Parker University Chiro Texpo 2025 Honorees: Young Chiropractor of the Year – Korey Rose, DC President's Award – Jon Blackwell, DC, and Korey Rose, DC Executive Director's Award – Steve Van Osdale, DC Regional Doctor of the Year – Region 1: Kaci Roach, DC, Region 2: Joseph Adams, DC Texas Women's Leadership and Service Award – Mary Collings, DC, and Clare Morgan, DC Student Leadership Award – Parker University Tri 9 student Hayden Hadley During Chiro Texpo 2025, TCA also announced and swore in its new executive officers for the 2025-2026 term, all of whom are Parker University graduates! TCA's executive officers preside over an executive committee, including four department coordinators in charge of TCA's state committees, as well as a board of directors comprised of representatives from TCA's 12 districts, which cover all of Texas. TCA's New Executive Officers for 2025-2026: Don White, DC, FICC – president Andrew Oteo, DC – vice president Korey Rose, DC – secretary/treasurer Todd Whitehead, DC (served as TCA's president in 2024-2025) – immediate past president Congratulations to all the leaders who were recognized and honored for their dedication to furthering the positive impact of chiropractic care in the state of Texas. About Parker University Parker University, the fastest-growing college in Dallas and the fourth-fastest-growing in Texas, was founded in 1982 by Dr. James William Parker as Parker College of Chiropractic. Today, the university serves over 2,300 students and offers more than 25 accredited academic programs and certificates, including its flagship Doctor of Chiropractic program, which is home to the second-largest chiropractic cohort in the world. Parker University also leads in innovation with master's degrees in Clinical Neuroscience, Strength and Human Performance, and Functional Nutrition. Additionally, five new board-approved programs are set to launch soon. Attachment The Texas Chiropractic Association (TCA) Recognizes Parker University and Several Alumni at Chiro Texpo 2025. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Newsweek
2 days ago
- Newsweek
Common Virus Found To Increase Cancer Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Those who have a specific antibody that is produced following infection from a common virus may be at greater risk of developing certain cancers, a new study from the International Agency for Research on Cancer (IARC) has found. Individuals who test positive for Epstein–Barr virus (EBV) capsid antigen (VCA-IgA) antibodies were found to have a higher risk of developing cancers such as lung cancer, liver cancer, nasopharyngeal carcinoma and lymphoma, according to a study shared by IARC with Newsweek. Newsweek has contacted the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services (HHS) via email for comment. What Is Epstein-Barr Virus? The Epstein-Barr virus is one of the most common and persistent human viruses in the world, according to the CDC, and is member of the herpes virus family. EBV infects approximately 95 percent of the global population, the IARC said. It is the usual cause of infectious mononucleosis, otherwise known as "mono"—a contagious disease common among teens and adults that is usually spread through saliva, so by kissing or sharing drinks and food. After an individual is infected with EBV, the virus becomes inactive in their body, but may reactivate in some cases, with the potential for symptoms to resurface. "It's a latent virus that resides inside of certain cells," Dr. Henry Balfour Jr., a professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota Medical School, told Newsweek. "So, when your immune system is challenged, let's say you get a flu shot or COVID, you're likely to see reactivation of EBV," he said. Usual symptoms of EBV include fatigue, fever, inflamed throat, swollen lymph nodes in the neck, an enlarged spleen and swollen liver, as well as others. The virus was previously classified as carcinogenic to humans, in the IARC's highest risk category (Group 1), in 1997. To date, it has been directly linked to a few specific types of cancer, with studies estimating EBV-related cases accounted for between 239,700 to 357,900 new cases of certain cancers in 2020. EBV has also been linked with rare diseases like multiple sclerosis (MS), a chronic and autoimmune neurological disorder, Lawrence Steinman, a professor of neurology and neurological sciences, and pediatrics at Stanford University, told Newsweek. He also said that EBV, as a virus, may "trigger cancer itself," but that the antibodies one gets from EBV infection, may actually fight against certain cancers. "In fact, strengthening the immune response to EBV is a way that the immune system fights the virus, and in doing so helps kill the cancer or attenuate its spread," he said. "The trade off comes with developing an autoimmune response to self proteins that may be contained in the cancer." File photo: a computer illustration of the Epstein-Barr virus (EBV). File photo: a computer illustration of the Epstein-Barr virus (EBV). Dr_Microbe/Getty Images What Did The Study Find? The IARC study evaluated the cancer risk in two cohorts in Southern China of just under 74,000 adults. Over the course of around eight to 10 years, 964 cases of cancer were identified in the Zhongshan cohort and 1,026 in the Wuzhou cohort. Researchers found that those who tested positive for EBV VCA-IgA antibodies were nearly five times as likely to develop cancer compared with individuals who tested negative. There were also higher risks of developing certain cancers—for nasopharyngeal carcinoma, EBV VCA-IgA antibody positive individuals were found to be 26 times as likely to develop the disease. Meanwhile, for lung cancer, they were 1.76 times as likely to develop the disease, for liver cancer, they were 1.70 times as likely to, and for lymphoma, they were 3.20 times as likely to. Nasopharyngeal carcinoma, a type of cancer affecting the part of the throat that connects the back of the nose to the back of the mouth, had the highest risk among the cancer types investigated. Authors of the study noted there was an increased cancer risk associated with higher levels of EBV VCA-IgA antibodies—an elevated risk that persisted even up to 10 years before diagnosis, which the IARC said suggested that EBV infection "may play a long-term role in cancer development." Overall, the study estimated that 7.8 percent of the total cancer burden in Southern China could be attributed to EBV VCA-IgA antibody positivity in individuals. Are Experts Concerned? "I am not concerned about this finding," Luis Schang, a professor of chemical virology at Cornell University, told Newsweek, because it has been "long known" that EBV is associated with certain cancers. "The major contribution of this study is linking the increase in cancer risk to likely reactivation," he said. Before this study, he said that it would be argued the risk of developing cancer was "independent" of virus reactivation. Schang said that the study could also indicate that "antiviral, or vaccine, suppressive treatment could have a protective effect against the cancers produced by EBV." Antiviral treatment can "inhibit" virus reactivation, Schang said, although it is still "extremely challenging" to treat, as the virus persists in human cells for a prolonged period. He added that a vaccine that "could elicit strong immune responses" to curtail reactivation at early stages, potentially having an impact oncogenesis, the process where cells are transformed into cancer cells. While the findings are notable, experts told Newsweek that more research still needs to be done on the issue. "Most people, almost everybody who is infected with EBV, doesn't get cancer and doesn't get multiple sclerosis, so there's something else going on," Balfour Jr said. He said that there is evidence of the effects of EBV, and its potential to cause long-term chronic diseases like cancer or autoimmune diseases, being "specific to geographical area and possibly the socioeconomic status of the people." While it is not yet clear why this is the case, he said that "over and over again, socioeconomic status and race ethnicity are associated with the prevalence of EBV." As a result, "I would be cautious in interpreting these findings to be of any concern to people in the U.S. - depending on your age and your socioeconomic status, about 90 percent of young adults and adults are positive for EBV and almost all of them are not going to get cancers or autoimmune diseases such as MS," Balfour said.
New York Post
2 days ago
- New York Post
UN says millions will die by 2029 is HIV funding programs aren't replaced
Years of American-led investment into AIDS programs has reduced the number of people killed by the disease to the lowest levels seen in more than three decades, and provided life-saving medicines for some of the world's most vulnerable. But in the last six months, the sudden withdrawal of U.S. money has caused a 'systemic shock,' U.N. officials warned, adding that if the funding isn't replaced, it could lead to more than 4 million AIDS-related deaths and 6 million more HIV infections by 2029. 8 A worker in a lab loads HIV/malaria test cassettes into a machine. REUTERS 8 Winnie Byanyima speaking at the UNAIDS Global AIDS Update 2025. AP 'The current wave of funding losses has already destabilized supply chains, led to the closure of health facilities, left thousands of health clinics without staff, set back prevention programs, disrupted HIV testing efforts and forced many community organizations to reduce or halt their HIV activities,' UNAIDS said in a report released Thursday. UNAIDS also said that it feared other major donors might also scale back their support, reversing decades of progress against AIDS worldwide — and that the strong multilateral cooperation is in jeopardy because of wars, geopolitical shifts and climate change. The $4 billion that the United States pledged for the global HIV response for 2025 disappeared virtually overnight in January when U.S. President Donald Trump ordered that all foreign aid be suspended and later moved to shutter the U.S. AID agency. Andrew Hill, an HIV expert at the University of Liverpool who is not connected to the United Nations, said that while Trump is entitled to spend U.S. money as he sees fit, 'any responsible government would have given advance warning so countries could plan,' instead of stranding patients in Africa when clinics were closed overnight. 8 A patient shows a Vulante tablet. AFP via Getty Images 8 South Africa's Minister of Health Aaron Motsoaledi speaking at a UNAIDS report release. AP The U.S. President's Emergency Plan for AIDS Relief, or PEPFAR, was launched in 2003 by U.S. President George W. Bush, the biggest-ever commitment by any country focused on a single disease. UNAIDS called the program a 'lifeline' for countries with high HIV rates, and said that it supported testing for 84.1 million people, treatment for 20.6 million, among other initiatives. According to data from Nigeria, PEPFAR also funded 99.9% of the country's budget for medicines taken to prevent HIV. 8 Mosele Mothibi, 40, an unemployed textile factory worker, holds her ARV tablets. Getty Images 8 Colorized electron microscope image of a T cell under attack by HIV. AP In 2024, there were about 630,000 AIDS-related deaths worldwide, per a UNAIDS estimate — the figure has remained about the same since 2022 after peaking at about 2 million deaths in 2004. Even before the U.S. funding cuts, progress against curbing HIV was uneven. UNAIDS said that half of all new infections are in sub-Saharan Africa. Tom Ellman, of the charity Doctors Without Borders, said that while some poorer countries were now moving to fund more of their own HIV programs, it would be impossible to fill the gap left by the U.S. 'There's nothing we can do that will protect these countries from the sudden, vicious withdrawal of support from the U.S.,' said Ellman, director of Doctors Without Borders' South Africa Medical Unit. Experts also fear another loss: data. The U.S. paid for most HIV surveillance in African countries, including hospital, patient and electronic records, all of which has now abruptly ceased, according to Dr. Chris Beyrer, director of the Global Health Institute at Duke University. 8 South Africa's Minister of Health Aaron Motsoaledi, right, speaks as Winnie Byanyima, Executive Director of UNAIDS and Under-Secretary-General of the United Nations watches on during the UNAIDS report release at Bertha Gxowa Hospital in Germiston, South Africa. AP 8 Workers in a Nigerian factory package HIV test kits. REUTERS 'Without reliable data about how HIV is spreading, it will be incredibly hard to stop it,' he said. The uncertainty comes as a twice-yearly injectable could end HIV, as studies published last year showed that the drug from pharmaceutical maker Gilead was 100% effective in preventing the virus. At a launch event Thursday, South Africa's health minister Aaron Motsoaledi said the country would 'move mountains and rivers to make sure every adolescent girl who needs it will get it,' saying that the continent's past dependence upon US aid was 'scary.' Last month, the U.S. Food and Drug Administration approved the drug, called Yeztugo, a move that should have been a 'threshold moment' for stopping the AIDS epidemic, said Peter Maybarduk of the advocacy group Public Citizen. But activists like Maybarduk said Gilead's pricing will put it out of reach of many countries that need it. Gilead has agreed to sell generic versions of the drug in 120 poor countries with high HIV rates but has excluded nearly all of Latin America, where rates are far lower but increasing. 'We could be ending AIDS,' Maybarduk said. 'Instead, the U.S. is abandoning the fight.'
